Categories Analysis, Health Care

Biocept (BIOC) – Is it worth buying?

From its 52-week high of $1.15 achieved last July, BIOC stock fell below $1 mark in the following month and continued to trade below $1.

Investing in microcap stocks are considered to be risky; even higher so in uncertain market environments like the one we are seeing right now. So what’s the case with Biocept (NASDAQ: BIOC)?

Biocept overview

Biocept, a cancer diagnostics and research company, was founded 23 years ago and became a public company in 2014. Biocept develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) assays using a standard blood sample. The company generates revenues by:

  • Providing laboratory services to medical oncologists, surgical oncologists, urologists, pulmonologists, pathologists and other physicians
  • Providing laboratory services to pharmaceutical and biopharmaceutical companies, which are developing cancer treatment drugs
  • Licensing and/or selling its proprietary testing and/or technologies to partners in the US and abroad

Recent financial performance

The San Diego, California-based biotech firm posted net losses of $24.6 million in fiscal 2018 and $25.1 million in fiscal 2019. Revenue surged 70% year-over-year to $5.53 million in fiscal 2019. For the first quarter ended March 31, 2020, net loss attributable to common shareholders widened to $8.34 million from $6.02 million in the prior-year quarter.

Biocept (BIOC) - Why it’s a riskier investment?

NASDAQ compliance

From its 52-week high of $1.15 achieved last July, BIOC stock fell below $1 mark in the following month and continued to trade below $1. In September 2019, Biocept received a notification from NASDAQ for not complying with the minimum closing bid price of $1. In March 2020, the molecular oncology diagnostic company received a 180-day extension from NASDAQ to regain the compliance.

Also read: Biocept Inc. (BIOC) Q2 2020 Earnings Call Transcript

After the one-for-thirty reverse stock split in July 2018, Biocept has planned to seek shareholder approval again for its reverse stock split in a reconvened virtual Annual Meeting on July 31, 2020.

Expenses

Biocept anticipates R&D expenses to remain consistent in the near-term and costs related to collaborations with research and academic institutions to increase. Sales and marketing expenses are expected to increase as the company works on generating higher revenues and marketing additional offerings. General and administrative expenses are also expected to increase as Biocept expands its business operations.

Also read: Biocept (BIOC) revenue drops 23% in Q2 2020; loss narrows

COVID-19 testing

In late June, Biocept announced the availability of 10,000 oropharyngeal specimen collection kits for COVID-19 testing. In an email communication with AlphaStreet, the company spokesperson said its too early to provide daily average testing numbers, as its been only a few weeks that COVID-19 testing kits became available.

The company spokesman added,

“Securing specimen collection kits to conduct COVID-19 testing has been challenging both for Biocept and other providers.  We are working towards offering Biocept-developed specimen collection kits while making available kits with parts Biocept assembles from another provider. We expect our proprietary Biocept-developed COVID-19 collection kits to be available in the third quarter of 2020.”

The global outbreak of the COVID-19 continues to rapidly evolve, and the effect of COVID-19 will depend on the future developments. While Biocept receives specimens from clients on a daily basis, it anticipates a potential slowdown in volume as many clinic visits are being re-scheduled and delayed.

Final verdict

As of March 31, 2020, Biocept had $21.5 million in cash and an accumulated deficit of $254.1 million. While the company is currently in the commercialization stage of operations, it has not yet achieved profitability and anticipates net losses and negative cash flows from operations to continue for the foreseeable future. As revenues grow, sales and marketing and R&D expenses are estimated to continue to grow, albeit at a slower rate. The company needs to generate significant growth in revenues to achieve and sustain income from operations.

Two analysts have recommended buying BIOC stock with a price target of $1.53. Shares of Biocept have given a positive return of about 140% since the beginning of this year. Despite COVID-19 pandemic disrupting Biocept’s business in many ways, it had also given some benefits. With the expected increase in COVID-19 testing capabilities in the third quarter, Biocept is expected to perform better in the rest of 2020. Yet, the continuous losses and higher cash burn remain headwinds for the company.

DISCLAIMER: This article does not necessarily imply the views of AlphaStreet, and contains opinions of the author alone.

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Comments

  1. Pingback: Lincoln Georgis
  2. Pingback: Chirurgie Tunisie
  3. Pingback: Local society
  4. Pingback: Pharmacognos
  5. Pingback: research
  6. Pingback: Academic Advising
  7. Pingback: Bachelor's Degree
  8. Pingback: Medication safety
  9. Pingback: lean biome
  10. Pingback: Fiverr Earn
  11. Pingback: Fiverr Earn
  12. Pingback: Fiverr Earn
  13. Pingback: Fiverr Earn
  14. Pingback: Fiverr Earn
  15. Pingback: Fiverr Earn
  16. Pingback: Fiverr Earn
  17. Pingback: Fiverr Earn
  18. Pingback: fiverrearn.com
  19. Pingback: fiverrearn.com
  20. Pingback: fiverrearn.com
  21. Pingback: Freight Broker
  22. Pingback: fiverrearn.com
  23. Pingback: clima hoy
  24. Pingback: fiverrearn.com
  25. Pingback: french terrier
  26. Pingback: morkie poo
  27. Pingback: cavapoo dog
  28. Pingback: Intertising
  29. Pingback: isla mujeres
  30. Pingback: bitcoin
  31. Pingback: sorority jewelry
  32. Pingback: Silver earrings
  33. Pingback: Samsung phone
  34. Pingback: future university
  35. Pingback: future university
  36. Pingback: future university
  37. Pingback: future university
  38. Pingback: future university
  39. Pingback: Fiverr.Com
  40. Pingback: Warranty
  41. Pingback: Piano maintenance
  42. Pingback: FUE
  43. Pingback: FUE
  44. Pingback: Office packing
  45. Pingback: Classic Books 500
  46. Pingback: FiverrEarn
  47. Pingback: Streamer
  48. Pingback: partners
  49. Pingback: metafast
  50. Pingback: Public Policy
  51. Pingback: red boost reviews
  52. Pingback: FiverrEarn
  53. Pingback: FiverrEarn
  54. Pingback: live sex cams
  55. Pingback: live sex cams
  56. Pingback: FiverrEarn
  57. Pingback: FiverrEarn
  58. Pingback: FiverrEarn
  59. Pingback: FiverrEarn
  60. Pingback: FiverrEarn
  61. Pingback: dictionary
  62. Pingback: Kuliah Termurah
  63. Pingback: FiverrEarn
  64. Pingback: FiverrEarn
  65. Pingback: FiverrEarn
  66. Pingback: cheap sex cams
  67. Pingback: OnOverseas.Com
  68. Pingback: live sex cams
  69. Pingback: frt trigger
  70. Pingback: 늑대닷컴
  71. Pingback: Slot online
  72. Pingback: One Peace AMV
  73. Pingback: nang sydney
  74. Pingback: superslot
  75. Pingback: allgame
  76. Pingback: 918kiss
  77. Pingback: หวย24
  78. Pingback: moisturizer
  79. Pingback: pg slot
  80. Pingback: megagame
  81. Pingback: 44 mag ammo
  82. Pingback: itsMasum.Com
  83. Pingback: nangs sydney
  84. Pingback: nangs Sydney
Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top